

AMENDMENTS TO THE CLAIMS:


Please amend claim 68, as shown below.

This listing of claims will replace all prior versions and listings of claims in the

Application:

Claims 1-35 (cancelled)


Claim 36 (previously presented): A compound having the formula:




Ia

wherein:

R₁ represents a radical selected from the group consisting of



alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R₉, -OR₉,



R_2 and R_3 are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R_4 is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and $-NR_{12}R_{13}$;

R_5 and R_7 are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{14}$ and $-(C=O)R_9$;

R_6 , R_8 , R_{12} , and R_{13} are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{15}$ and $-(C=O)R_9$;

or R_5 and R_6 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R_7 and R_8 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R_9 is a radical of the formula $-W-O(C=O)-CH_3$, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

R₁₀ and R₁₁ are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R₁₄ is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R₁₅ is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group, and pharmaceutically acceptable salts of said compound.

Claim 37 (previously presented): A compound according to claim 36, selected from the group consisting of:

2,2'-[[3-(2,2,2-Trifluoroethyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(4-Morpholinyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(1-Piperidinyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(4-Morpholinylsulfonyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(Methoxyethoxy)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-Bis(phenylmethyl)amino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[1-(4-Methylpiperazinyl)methyl]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(Diethylaminomethyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-(Dimethylaminomethyl)phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[4-(Morpholinyl)methyl]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(4-Hydroxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[2-(1,1-Dioxide-2,3,4,5-tetrahydro)isothiazolyl]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(3-Hydroxypropyl)-N-ethylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(2-Hydroxyethyl)-N-ethylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[1-(4-Hydroxypiperidiny)]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(3-Hydroxypropyl)-N-methylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(4-Acetoxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(2-Hydroxyethyl)-N-methylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

2,2'-[[3-[N-(4-Hydroxybutyl)-N-methylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol];

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567


2,2'-[[3-[N-(2-Hydroxyethyl)-N-propylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-propylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;


2,2'-[[3-[N-(6-Hydroxyhexyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol; and

2,2'-[[3-[N-(5-Hydroxypentyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 38 (previously presented): The compound according to claim 36 having the formula:



Claim 39 (previously presented): The compound according to claim 36 having the formula:



Claim 40 (previously presented): The compound according to claim 36 having the name 2,2'-[[3-[N-(4-Hydroxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 41 (previously presented): The compound according to claim 36 having the name 2,2'-[[3-[N-(2-Hydroxyethyl)-N-methylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 42 (previously presented): The compound according to claim 36 having the name 2,2'-[[3-[N-(2-Hydroxyethyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 43 (previously presented): A pharmaceutical composition for treating or preventing pneumovirus infection, said composition comprising a compound according to claim 36 in an amount effective to attenuate infectivity of said virus, and a pharmaceutically acceptable carrier medium.

Claim 44 (previously presented): A pharmaceutical composition according to claim 43, further comprising at least one supplemental active agent selected from the group consisting of

interferon, ribavirin and an immunomodulator, an immunoglobulin, an anti-inflammatory agent, an antibiotic, an anti-viral and an anti-infective.

Claim 45 (previously presented): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises ethanol.

Claim 46 (previously presented): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises propylene glycol.

Claim 47 (previously presented): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises water.

Claim 48 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 50% ethanol.

Claim 49 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 60% ethanol.

Claim 50 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 70% ethanol.

Claim 51 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 80% ethanol.

Claim 52 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 90% ethanol.

Claim 53 (previously presented): A pharmaceutical composition according to claim 52, wherein said pharmaceutically composition comprises less than 5% water.

Claim 54 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically acceptable carrier medium comprises ethanol, water, and propylene glycol.

Claim 55 (previously presented): A pharmaceutical composition according to claim 54, wherein said pharmaceutically composition comprises about 85% ethanol, about 10% propylene glycol, and about 5% water.

Claim 56 (previously presented): A method of treatment of pneumovirus infection in a patient in need of said treatment, said method comprising administering to said patient a therapeutically effective amount of a compound according to claim 36.

Claim 57 (previously presented): A method as claimed in claim 56, wherein said compound is administered through inhalation or intubation.

Claim 58 (previously presented): A method as claimed in claim 56, wherein said compound is administered by an electrohydrodynamic delivery device.

Claim 59 (previously presented): A method as claimed in claim 56, wherein said electrohydrodynamic delivery device is hand-held.

Claim 60 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device is disposable.

Claim 61 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device is for a single user.


Claim 62 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device comprises a removable mouthpiece.

Claim 63 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device comprises a mask.

Claim 64 (previously presented): A method of treating cells in culture that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said cultures an effective amount of a compound according to claim 36.


Claim 65 (previously presented): A method of treating biological materials that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said materials an effective amount of a compound according to claim 36.

Claim 66 (previously presented): A compound having the formula:




wherein:

R_1' represents a radical selected from the group consisting of



alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R_9 , $-OR_9$,



R_2 and R_3 are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R_4 is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and $-NR_{12}R_{13}$;

R_5 and R_7 are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{14}$ and $-(C=O)R_9$;

R_6 , R_8 , R_{12} , and R_{13} are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{15}$ and $-(C=O)R_9$;

or R_5 and R_6 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R_7 and R_8 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R_9 is a radical of the formula $-W-O(C=O)-CH_3$, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;


R_{10} and R_{11} are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R_{14} is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R_{15} is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group, and pharmaceutically acceptable salts of said compound.

Claim 67 (cancelled).

Claim 68 (currently amended): A compound having the formula:




III

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643


175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567


wherein R_b is selected from the group consisting of $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CH}_3$, -

$\text{CH}(\text{CH}_3)\text{OCH}_2\text{CH}_3$, $-\text{CH}_2-\text{OCH}_2\text{CH}_2-\text{OCH}_3$, , $-\text{CH}_2-\text{OCH}_2\text{CH}_2-\text{Si}(\text{CH}_3)_3$, $-\text{CH}_3$, -
 $\text{CH}_2\text{C}_6\text{H}_5$, $-(\text{CH}_2)_2\text{Si}(\text{CH}_3)_3$, $-\text{CON}(\text{R}_c\text{R}_d)_2$, $-\text{CSN}(\text{R}_c\text{R}_d)_2$, and $-\text{PO}(\text{NR}_c\text{R}_d)_2$;

R_c and R_d are independently selected from an alkyl group;

R_1'' represents a radical selected from the group consisting of

, $-\text{NR}_5\text{R}_6$, $-\text{SO}_2\text{NR}_7\text{R}_8$, hydroxyalkyl, hydroxyalkoxy, polyhydroxyalkyl, alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R_9 , $-\text{OR}_9$,

; n being an integer from 1 to 4;

R_2 and R_3 are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R_4 is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and $-\text{NR}_{12}\text{R}_{13}$;

R_5 and R_7 are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(\text{C}=\text{O})\text{R}_{14}$ and $-(\text{C}=\text{O})\text{R}_9$;

R_6 , R_8 , R_{12} , and R_{13} are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(\text{C}=\text{O})\text{R}_{15}$ and $-(\text{C}=\text{O})\text{R}_9$;

or R_5 and R_6 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing

one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R_7 and R_8 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R_9 is a radical of the formula $-W-O(C=O)-CH_3$, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

R_{10} and R_{11} are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R_{14} is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group; and

R_{15} is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group.

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567